A 67-year-old with type 2 diabetes and PAD asks about SGLT2 inhibitors' effect on PAD amputations. Per ADA 2025, which is accurate?...

Question

A 67-year-old with type 2 diabetes and PAD asks about SGLT2 inhibitors' effect on PAD amputations. Per ADA 2025, which is accurate?

Accepted Answer

SGLT2 inhibitors reduce HF/renal outcomes; monitor PAD carefully but not a class-wide amputation signal

Answer

SGLT2 inhibitors increase amputation risk across the class

Answer

No agent has PAD data

Answer

Avoid SGLT2 in PAD categorically

Answer

They treat claudication

us-abim MCQ (SBA): Type 2 Diabetes (PAD considerations)